A securities class action has been filed against Doximity, Inc. (DOCS) on behalf of all persons and entities that purchased or otherwise acquired Doximity common stock between August 8, 2024 through May 13, 2026. This case has been filed in the USDC – NDCA.
Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking. Doximity is frequently referred to as the “LinkedIn for doctors.” Its platform is, with a few exceptions, free to use for its medical professional members.
The complaint alleges tha throughout the Class Period, Doximity claimed that the Company’s Newsfeed was its “biggest revenue driver.” Specifically, Defendants claimed that the Company’s growth was “led by our Newsfeed, which is both our most used and most monetized product” and told investors that the Newsfeed was consistently “reach[ing] new highs,” with “an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped.” In addition, Doximity touted its “deep engagement,” assuring investors that Doximity does not “bombard physicians with ads and messages in hopes of getting lucky” and assured investors that “[Doximity does not] have an e-newsletter product.”
In truth, Doximity overstated the impact that its Newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods.
As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s common stock pursuant to the revelation of the fraud, Plaintiff and other Class members have suffered significant losses and damages.